Tohidi Mehdi, Allahyari Abolghasem, Ataei Azimi Sajjad, Alimi Hedieh, Elyasi Sepideh, Qoorchi Moheb Seraj Farid, Mehrad-Majd Hasan
Department of Hematology and Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Vascular and Endovascular Surgery Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
J Oncol Pharm Pract. 2024 Sep 2:10781552241277958. doi: 10.1177/10781552241277958.
Anthracycline drugs play a fundamental role in breast cancer treatment; however, the cardiotoxicity side effects obscure the advantages of treatment. Curcumin has antioxidant and anti-inflammatory effects.
In this study, we investigated the effect of nanocurcumin supplementation on Doxorubicin induced Cardiotoxicity. In this randomized clinical trial, a week before starting the doxorubicin regimen for breast cancer patients, the control group received placebo and curcumin group received 80 mg daily dosage of nano curcumin capsules for six months. Echocardiography parameter changes before chemotherapy and after six months were evaluated.
46 patients were included. Left ventricle (LV) ejection fraction significantly decreased and LV end diastolic volume significantly increased in control group but no significant changes were observed in the curcumin group (LVEF: 2.62 ± 59.35 to 4.23 ± 56.85, -value: 0.014 vs 59.55 ± 1.91 to 58.46 ± 3.41, -value:0.135; LVEDV: 77.09 ± 15.33 to 80.65 ± 14.54, -value:0.023 vs 72.41 ± 15.34 74.00 ± 14.25, -value: 0.294). Additionally, LVEF, LV end systolic diameter (LVESD), and end diastolic diameter (LVEDD) insignificantly more decreased in control group versus curcumin group (LVEF: 4.13 ± 2.50- vs 3.36 ± 1.08-, -value: 0.223; LVESD: 0.27 ± 0.06-vs 0.120.45 ±, -value:0.110; LVEDD: -0.44 ± 0.33 vs 0.070.33 ±, -value:0.269). Furthermore, symptomatic cardiomyopathy and ejection fraction ratio less than 53% were not observed. The LVEF reduction >15% was observed was also high in the control group, (-value = 0.020).
This study shows the possible effect of nanocurcumin capsules to reduce the cardiotoxicity of anthracycline chemotherapy medications.
蒽环类药物在乳腺癌治疗中发挥着重要作用；然而，心脏毒性副作用掩盖了治疗的优势。姜黄素具有抗氧化和抗炎作用。
在本研究中，我们调查了纳米姜黄素补充剂对阿霉素诱导的心脏毒性的影响。在这项随机临床试验中，在乳腺癌患者开始阿霉素治疗方案前一周，对照组接受安慰剂，姜黄素组每天服用80毫克纳米姜黄素胶囊，持续6个月。评估化疗前和6个月后的超声心动图参数变化。
纳入46例患者。对照组左心室（LV）射血分数显著降低，左心室舒张末期容积显著增加，但姜黄素组未观察到显著变化（左心室射血分数：从2.62±59.35降至4.23±56.85，P值：0.014，而姜黄素组为59.55±1.91至58.46±3.41，P值：0.135；左心室舒张末期容积：从77.09±15.33增至80.65±14.54，P值：0.023，而姜黄素组为72.41±15.34至74.00±14.25，P值：0.294）。此外，与姜黄素组相比，对照组的左心室射血分数、左心室收缩末期直径（LVESD）和舒张末期直径（LVEDD）下降幅度无显著差异（左心室射血分数：4.13±2.50对3.36±1.08，P值：0.223；LVESD：0.27±0.06对0.12±0.45，P值：0.110；LVEDD：-0.44±0.33对0.07±0.33，P值：0.269）。此外，未观察到有症状的心肌病和射血分数比低于53%的情况。对照组中左心室射血分数降低>15%的情况也较高（P值=0.020）。
本研究表明纳米姜黄素胶囊可能具有降低蒽环类化疗药物心脏毒性的作用。
